

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTXC:504/WIM

08/726,211

List of Patents and Publications for Applicant's

Applicant

Mar Tormo, et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 4, 1996

Group:

UNKNOWN 1636

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	0 252 685	1-13-88	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
AV	C1	Allsopp <i>et al.</i> , "The Proto-Oncogene bcl-2 Can Selectively Rescue Neurotrophic Factor-Dependent Neurons from Apoptosis," <i>Cell</i> , 73:295, 1993.
AV	C2	Bakhshi <i>et al.</i> , "Cloning the Chromosomal Breakpoint of t(14;18) Human Lymphomas: Clustering around J _H on Chromosome 14 and near a Transcriptional Unit on 18," <i>Cell</i> , 41:899, 1985.
AV	C3	Boise, <i>et al.</i> , "bcl-x, a bcl-2-Related Gene That Functions as a Dominant Regulator of Apoptotic Cell Death", <i>Cell</i> , 74:597-608, 1993.
AV	C4	Borzillo <i>et al.</i> , "Bcl-2 Confers Growth and Survival Advantage to Interleukin 7-dependent Early Pre-B Cells Which Become Factor Independent by a Multistep Process in Culture," <i>Oncogene</i> , 7:869, 1992.
AV	C5	Campos <i>et al.</i> , "Effects of BCL-2 Antisense Oligodeoxynucleotides on In Vitro Proliferation and Survival of Normal Marrow Progenitors and Leukemic Cells," <i>Blood</i> , 84:595, 1994.
AV	C6	Cazals-Hatem <i>et al.</i> , "Molecular Cloning and DNA Sequence Analysis of cDNA Encoding Chicken Homologue of the Bcl-2 Oncoprotein," <i>Biochim. Biophys. Acta</i> , 1132:109, 1992.
AV	C7	Chao, <i>et al.</i> , "Bcl-x _L and Bcl-2 Repress a Common Pathway of Cell Death," <i>J. Exp. Med.</i> , 182:821-828, 1995.
AV	C8	Chen <i>et al.</i> , "Suppression of Bcl-2 Messenger RNA Production May Mediate Apoptosis after Ionizing Radiation, Tumor Necrosis Factor α , and Ceramide," <i>Cancer Res.</i> , 55:991-994, 1995.

EXAMINER:

MHA

DATE CONSIDERED:

3/2/98

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No. UTXC:504/WIM	Serial No. 08/726,211
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mar Tormo, et al.	
		Filing Date: October 4, 1996	Group: UNKNOWN 1636
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>CV</i>	C9	Chen-Levy and Cleary, "Membrane Topology of the Bcl-2 Protooncogenic Protein Demonstrated <i>in Vitro</i> ," <i>J. Biol. Chem.</i> 265:4929, 1990.
<i>CV</i>	C10	Chen-Levy <i>et al.</i> , "The <i>bcl-2</i> Candidate Proto-Oncogene Product Is a 24-Kilodalton Integral-Membrane Protein Highly Expressed in Lymphoid Cell Lines and Lymphomas Carrying the t(14;18) Translocation," <i>Mol. Cell. Biol.</i> , 9:701, 1989.
<i>CV</i>	C11	Cheng <i>et al.</i> , "Bax-independent inhibition of apoptosis by Bcl-x _L ," <i>Nature</i> , 279:554-556, 1996.
<i>CV</i>	C12	Chittenden <i>et al.</i> , "Induction of apoptosis by the Bcl-2 homologue Bak," <i>Nature</i> , 374:733, 1995.
<i>CV</i>	C13	Choi <i>et al.</i> , "The role of bcl-X _L in CD40-mediated rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells," <i>Eur. J. Immunol.</i> , 25:1352-1357, 1995.
<i>CV</i>	C14	Clarke <i>et al.</i> , "A recombinant <i>bcl-x_s</i> adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells," <i>Proc. Natl. Acad. Sci. USA</i> , 92:11024-11028, 1995.
<i>CV</i>	C15	Cleary <i>et al.</i> , "Cloning and Structural Analysis of cDNAs for <i>bcl-2</i> and a Hybrid <i>bcl-2</i> /Immunoglobulin Transcript Resulting from the t(14;18) Translocation," <i>Cell</i> , 47:19, 1986.
<i>CV</i>	C16	Cuende <i>et al.</i> , Programmed cell death by <i>bcl-2</i> -dependent and independent mechanisms in B lymphoma cells," <i>EMBO J.</i> , 12:1555-1560, 1993.
<i>CV</i>	C17	Datta <i>et al.</i> , "Overexpression of Bcl-x _L by Cytotoxic Drug Exposure Confers Resistance to Ionizing Radiation-induced Internucleosomal DNA Fragmentation," <i>Cell Growth & Differentiation</i> , 6:363-370, 1995.
<i>CV</i>	C18	Dole <i>et al.</i> , "Bcl-x _L Is Expressed in Neuroblastoma Cells and Modulates Chemotherapy-Induced Apoptosis," <i>Cancer Res.</i> , 55:2576-2582, 1995.
<i>CV</i>	C19	Duke <i>et al.</i> , "Morphological, biochemical and flow cytometric assays of apoptosis," <i>In: Coligan et al (eds) Current protocols in immunology</i> , vol 1., New York: John Wiley & sons, p 3.17.1, 1991.
<i>CV</i>	C20	Eguchi <i>et al.</i> , "Isolation and Characterization of the Chicken <i>bcl-2</i> Gene: Expression in a Variety of Tissues Including Lymphoid and Neuronal Organs in Adult and Embryo," <i>Nucl. Acids. Res.</i> , 20:4187, 1992.
<i>CV</i>	C21	Frankowski <i>et al.</i> , "Function and expression of the <i>Bcl-x</i> gene in the developing and adult nervous system," <i>NeuroReport</i> , 6:1917-1921, 1995.

EXAMINER:

John A. Hunter

DATE CONSIDERED:

3/2/98

EXAMINER: INITIAL IF REFERENCE CONSIDERED WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTXC:504/WIM	Serial No. 08/726,211
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mar Tormo, et al.	
		Filing Date: October 4, 1996	Group: UNKNOWN 1636
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>MW</i>	C22	Garcia <i>et al.</i> , "Prevention of Programmed Cell Death of Sympathetic Neurons by the <i>bcl-2</i> Prot-Oncogene," <i>Science</i> , 258:302, 1992.
<i>MW</i>	C23	González-García <i>et al.</i> , " <i>bcl-x</i> is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death," <i>Proc. Natl. Acad. Sci. USA.</i> , 92:4304-4308, 1995.
<i>MW</i>	C24	González-García <i>et al.</i> , " <i>bcl-x_L</i> is the major <i>bcl-x</i> mRNA form expressed during murine development and its product localizes to mitochondria," <i>Development</i> , 120:3033-3042, 1994.
<i>MW</i>	C25	Gottschalk <i>et al.</i> , "Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by <i>bcl-x</i> but not <i>bcl-2</i> ," <i>Proc. Natl. Acad. Sci. USA.</i> , 91:7350-7354, 1994.
<i>MW</i>	C26	Gottschalk <i>et al.</i> , "The ability of <i>Bcl-x_L</i> and <i>Bcl-2</i> to prevent apoptosis can be differentially regulated," <i>Death and Differentiation</i> , 3:113-118, 1996.
<i>AW</i>	C27	Graninger <i>et al.</i> , "Expression of <i>bcl-2</i> and <i>bcl-2</i> -Ig fusion transcripts in normal and neoplastic cells," <i>J. Clin. Invest.</i> , 80:1512, 1987.
<i>MW</i>	C28	Grillot <i>et al.</i> , " <i>bcl-x</i> Exhibits Regulated Expression During B Cell Development and Activation and Modulates Lymphocyte Survival in Transgenic Mice," <i>J. Exp. Med.</i> , 183:381-391, 1996.
<i>MW</i>	C29	Hockenberry <i>et al.</i> , " <i>Bcl-2</i> is an inner mitochondrial membrane protein that blocks programmed cell death," <i>Nature</i> , 348:334, 1990.
<i>AW</i>	C30	Jäättelä <i>et al.</i> , " <i>Bcl-x</i> and <i>Bcl-2</i> inhibit TNF and Fas-induced apoptosis and activation of phospholipase <i>A₂</i> in breast carcinoma cells," <i>Oncogene</i> , 10:2297-2305, 1995.
<i>AW</i>	C31	Jasty <i>et al.</i> , " <i>bcl-x_L</i> , A Gene Which Regulates Programmed Cell Death, Is Expressed In Neuroblastoma Tumor Cell Lines (abstract)," <i>Clinical Res.</i> , 42:416A, 1994.
<i>MW</i>	C32	Kiefer <i>et al.</i> , "Modulation of apoptosis by the widely distributed <i>Bcl-2</i> homologue Bak," <i>Nature</i> , 374: 736, 1995.
<i>AW</i>	C33	Kitada <i>et al.</i> , "Investigations of antisense oligonucleotides targeted against <i>bcl-2</i> RNAs," <i>Antisense Res. Dev.</i> , 3:157, 1993.
<i>AW</i>	C34	Kozopas <i>et al.</i> , " <i>MCL-1</i> , a gene expressed in programmed myeloid cell differentiation, has sequence similarity to <i>BCL-2</i> ," <i>Proc. Nat'l Acad. Sci. USA</i> , 90:3516, 1993.

EXAMINER:

Not a signature

DATE CONSIDERED:

3/2/98

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTXC:504/WIM	Serial No. 08/726,211
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mar Tormo, et al.	
		Filing Date: October 4, 1996	Group: UNKNOWN 1636
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>dw</i>	C35	Krajewski <i>et al.</i> , "Immunohistochemical Analysis of <i>In Vivo</i> Patterns of Bcl-x Expression," <i>Cancer Res.</i> , 54:5501-5507, 1994.
<i>dw</i>	C36	Kramer <i>et al.</i> , "Self-specific T lymphocyte lines as vehicles for gene therapy: myelin specific T cells carrying exogenous nerve growth factor gene (abstract)," <i>J. Cell. Biochem.</i> , Suppl. o (17 Part E):215, 1993.
<i>rw</i>	C37	Lin <i>et al.</i> , "Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to BCL-2," <i>J. Immunol.</i> , 151:1979, 1993.
<i>rw</i>	C38	McCarthy <i>et al.</i> , "Apoptosis in the development of the immune system: Growth factors, clonal selection and <i>bcl-2</i> ," <i>Cancer Metastasis Reviews</i> , 11:157-178, 1992.
<i>n</i>	C39	McDonnell <i>et al.</i> , "Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation," <i>Cell</i> , 57:79, 1989.
<i>rw</i>	C40	McDonnell, <i>et al.</i> , "The bcl-2-Immunoglobulin Transgenic Mouse: A Model of the t(14;18) Translocation in Human Follicular Lymphoma," <i>Transgene</i> , 1:47, 1993.
<i>dw</i>	C41	Minn <i>et al.</i> , "Expression of Bcl-x _L can Confer a Multidrug Resistance Phenotype," <i>Blood</i> , 86:1903-1910, 1995.
<i>n</i>	C42	Miyashita <i>et al.</i> , "Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression <i>in vitro</i> and <i>in vivo</i> ," <i>Oncogene</i> , 9:1799, 1994.
<i>dw</i>	C43	Núñez <i>et al.</i> , "BCL-X is expressed in embryonic and adult neuronal tissues and its expression prevents neuronal cell death (abstract)," <i>J. Cell. Biochem.</i> , Supplement 0 (19B), B8-438, p. 317, 1995.
<i>dw</i>	C44	Núñez <i>et al.</i> , "Deregulated BCL-2 gene expression selectively prolongs survival of growth factors-deprived hemopoietic cell lines," <i>J. Immunol.</i> , 144:3602, 1990.
<i>rw</i>	C45	Oltvai <i>et al.</i> , "Bcl-2 Heterodimerizes <i>In Vivo</i> with a Conserved Homolog, Bax, That Accelerates Programmed Cell Death," <i>Cell</i> 74:609-619, 1993.
<i>rw</i>	C46	Oppenheim <i>et al.</i> , "Brain-derived neurotrophic factor rescues developing avian motoneurons from cell death," <i>Nature</i> , 360:755-757, 1992.
<i>dw</i>	C47	Raff, M.C., "Social controls on cell survival and cell death," <i>Nature</i> , 356:397-400, 1992.
<i>dw</i>	C48	Reed <i>et al.</i> , "Bcl-2-mediated tumorigenicity in a human T-lymphoid cell line: synergy with c-myc and inhibition by Bcl-2 antisense," <i>Proc. Nat'l Acad. Sci. USA</i> , 87:3660, 1990b.

EXAMINER:

Pat A. Smith

DATE CONSIDERED:

3/2/98

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTXC:504/WIM	Serial No. 08/726,211
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mar Tormo, et al.	
		Filing Date: October 4, 1996	Group: UNKNOWN 1636
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>mn</i>	C49	Reed <i>et al.</i> , "Antisense-Mediated Inhibition Of BCL-2 Protooncogene Expression And Leukemic Cell Growth And Survival: Comparisons Of Phosphodiester and Phosphorothioate Oligodeoxynucleotides," <i>Cancer Res.</i> , 50: 6565, 1990.
<i>m</i>	C50	Reed <i>et al.</i> , "Regulation of <i>bcl-2</i> Proto-Oncogene Expression During Normal Human Lymphocyte Proliferation," <i>Science</i> , 236:1295, 1987.
<i>mn</i>	C51	Reed, <i>et al.</i> , "Bcl-2: prevention of apoptosis as a mechanism of drug resistance," <i>Hematol. Oncol. Clin. North Am.</i> , 9:451, 1995.
<i>mn</i>	C52	Sato <i>et al.</i> , "Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system," <i>Proc. Natl. Acad. Sci. USA</i> , 91:9238-9242, 1994.
<i>mn</i>	C53	Schott <i>et al.</i> , "Bcl-x _L protects cancer cells from p53-mediated apoptosis," <i>Oncogene</i> , 11(7):1389-1394, 1995.
<i>m</i>	C54	Schott, <i>et al.</i> , "BCL-X _L Protects Cells from P53-Mediated Apoptosis", <i>Journal of Investigative Medicine</i> 43 (SUPPL. 3) 458A, 1995
<i>mn</i>	C55	Sedlak <i>et al.</i> , "Multiple Bcl-2 family members demonstrate selective dimerization with Bax," <i>Proc. Nat'l Acad. Sci. USA</i> , 92:7834, 1995.
<i>mn</i>	C56	Sentman <i>et al.</i> , "bcl-2 Inhibits Multiple Forms of Apoptosis but Not Negative Selection in Thymocytes," <i>Cell</i> , 67:879, 1991.
<i>mn</i>	C57	Siegel <i>et al.</i> , "Inhibition of thymocyte apoptosis and negative and antigenic selection in <i>bcl-2</i> transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> , 89:7003, 1992.
<i>mn</i>	C58	Strasser <i>et al.</i> , "bcl-2 Transgene Inhibits T Cell Death and Perturbs Thymic Self-Censorship," <i>Cell</i> , 67:889, 1991.
<i>mn</i>	C59	Strasser <i>et al.</i> , "Enforced <i>BCL2</i> Expression in B-lymphoid Cells Prolongs Antibody Responses and Elicits Autoimmune Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8661, 1991.
<i>mn</i>	C60	Sumantran <i>et al.</i> , "Overexpression of Bcl-x _s Sensitizes MCF-7 Cells to Chemotherapy-Induced Apoptosis," <i>Cancer Res.</i> , 55:2507-2510, 1995.
<i>mn</i>	C61	Thompson, C. B., "Apoptosis in the Pathogenesis and Treatment of Disease," <i>Science</i> , 267:1456-1462, 1995.

EXAMINER:

Not a signature

DATE CONSIDERED:

3/2/98

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTXC:504/WIM	Serial No. 08/726,211
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mar Tormo, et al.	
		Filing Date: October 4, 1996	Group: UNKNOWN 1636
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>DS</i>	C62	Tormo <i>et al.</i> , "Antitumor activity of liposomal-bcl-2-antisense oligonucleotides in follicular lymphoma (abstract)," <i>Proc. Am. Assoc. Cancer. Res.</i> , 37:1190, 1996.
<i>DS</i>	C63	Tsujimoto and Croce, "Analysis of the structure, transcripts, and protein products of <i>bcl-2</i> , the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci. USA</i> , 83:5214, 1986.
<i>DS</i>	C64	Tsujimoto <i>et al.</i> , "Characterization of the protein product of <i>bcl-2</i> , the gene involved in human follicular lymphoma," <i>Oncogene</i> , 2:3, 1987.
<i>DS</i>	C65	Tsujimoto <i>et al.</i> , "The t(14;18) chromosome translocation involved in B-cell neoplasms result from mistakes in VDJ joining," <i>Science</i> , 229:1390, 1985.
<i>DS</i>	C66	Vaux <i>et al.</i> , " <i>Bcl-2</i> gene promotes haemopoietic cell survival and cooperates with <i>c-myc</i> to immortalize pre-B cells," <i>Nature</i> , 335:440, 1988.
<i>DS</i>	C67	Webb <i>et al.</i> , "Extrathymic Tolerance of Mature T Cells: Clonal Elimination as a Consequence of Immunity," <i>Cell</i> , 63:1249, 1990.
<i>DS</i>	C68	Williams, G.T., "Programmed Cell Death: Apoptosis and Oncogenesis," <i>Cell</i> , 65:1097-1098, 1991.
<i>DS</i>	C69	Wrone-Smith, <i>et al.</i> , "Discordant Expression of Bcl-x and Bcl-2 by Keratinocytes <i>in Vitro</i> and Psoriatic Keratinocytes <i>in Vivo</i> ," <i>Am. J. Pathology</i> , 146:1079-1088, 1995.
<i>DS</i>	C70	Yang <i>et al.</i> , "Bad, a Heterodimeric Partner for Bcl-X _L and Bcl-2, Displaces Bax and Promotes Cell Death," <i>Cell</i> , 80:285, 1995.
<i>DS</i>	C71	Yin <i>et al.</i> , "BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax," <i>Nature</i> , 369: 321, 1994.
<i>DS</i>	C72	Zhang <i>et al.</i> , "Gene therapy for the peripheral nervous system rat neuritogenic T cell line carry mouse nerve growth factor gene (abstract)," <i>J. Cell. Biochem.</i> , Suppl. 0 (17 Part E):SZ-116, 1993.

EXAMINER:

Pat A. Hunter

DATE CONSIDERED:

3/2/98

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
UTXC:504/CODSerial No.
08/726,211

List of Patents and Publications for Applicant's

Applicant
Mar Tormo, et al

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 4, 1996Group:
~~1806~~ 1636U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
<i>BA</i>	A1	5,015,568	05-14-91	Tsujimoto et al.	435	5	07-09-86
<i>BA</i>	A2	5,202,429	04-13-93	Tsujimoto et al.	536	23.5	04-19-91
<i>BA</i>	A3	5,459,251	10-17-95	Tsujimoto et al.	536	23.5	04-18-94
<i>BA</i>	A4	5,539,085	07-23-96	Bischoff et al.	530	350	08-20-93
<i>BA</i>	A5	5,539,094	07-23-96	Reed et al.	536	23.5	11-12-93
<i>BA</i>	A6	5,565,337	10-15-96	Diamond et al.	435	70.2	08-23-94
<i>BA</i>	A7	5,622,852	04-22-97	Korsmeyer	435	325	10-31-94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>BA</i>	B2	WO 93/24653	12-09-93	PCT	—	—	
<i>BA</i>	B3	WO 95/28497	10-26-95	PCT	—	—	
<i>BA</i>	B4	WO 96/27663	09-12-96	PCT	—	—	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>BA</i>	C73	Bradbury et al., "Down-Regulation of bcl-2 in AML Blasts by All-Trans Retinoic Acid and Its Relationship of CD34 Antigen Expression," British Journal of Haematology, 94:671-675, 1996.
<i>BA</i>	C74	Capaccioli et al., "A bcl-2/IgH Antisense Transcript Deregulates bcl-2 Gene Expression in Human Follicular Lymphoma t(14;18) Cell Lines," Oncogene, 13:105-115, 1996.
<i>BA</i>	C75	Masserano et al., "Dopamine Induces Apoptotic Cell Death of a Catecholaminergic Cell Line Derived from the Central Nervous System," Molecular Pharmacology, 50:1309-1315, 1996.

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTXC:504/COD

Serial No.

08/726,211

Applicant

Mar Tormo, et al

Filing Date:

October 4, 1996

Group:

~~1806~~ 1636

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>JA</i>	C76	Schendel et al., "Channel Formation by Antiapoptotic Protein Bcl-2," Proc. Natl. Acad. Sci. USA, 94:5113-5118, 1997.
<i>BN</i>	C77	Weber-Nordt et al., "Interleukin-10 Increases Bcl-2 Expression and Survival in Primary Human CD34+ Hematopoietic Progenitor Cells," Blood, 88(7):2549-2558, 1996.
<i>BN</i>	C78	Zhang et al., "BCL2 Regulates Neural Differentiation," Proc. Natl. Acad. Sci. USA, 93:4504-4508, 1996.

Examiner:

[Signature]

Date Considered:

3/2/98

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)Atty. Docket No.
UTXC:504/CODSerial No.
08/726,211

List of Patents and Publications for Applicant's

Applicant

INFORMATION DISCLOSURE STATEMENT

Tormo et al.

Filing Date:
October 4, 1996Group:
~~1805~~ 1636

Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

NOV 20 1997

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
<i>AN</i>	A8	5,227,170	07-13-93	Sullivan	424	450	06-20-90
<i>AN</i>	A9	5,135,917	08-04-92	Burch	514	44	07-12-90
<i>AN</i>	A10	5,178,875	01-12-93	Lenk et al.	424	450	01-14-91
<i>AN</i>	A11	4,950,432	08-21-90	Mehta et al.	264	4.6	10-16-87
<i>AN</i>	A12	5,417,978	05-23-95	Tari et al.	424	450	07-29-93

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>AN</i>	B5	WO 95/03788	02-09-95	PCT	—	—	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>AN</i>	C79	Aktar et al., "Liposome Delivery of Antisense Methylphosphonate and Phosphorothioate Oligonucleotides: A Study with MLV, FATMLV, and LUV Liposomes," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> , 19:345-346, 1992.
<i>AN</i>	C80	Clarenc et al., "Delivery of Antisense Oligonucleotides by poly(L-Lysine) Conjugation and Liposome Encapsulation," <i>Anti-Cancer Drug Design</i> , 8:81-94, 1993.
<i>AN</i>	C81	Gomez-Manzano et al., "Bax, Bcl-2 and p53 Interactions Modulate p53-Induced Apoptosis in Glioma Cells," <i>Proceedings of the American Association for Cancer Research</i> , 37:204, Abstract 1397, March 1996.
<i>AN</i>	C82	Juliano et al., "Liposomes as a Drug Delivery System for Antisense Oligodeoxynucleotides Encapsulated by Liposomes," <i>Antisense Research and Development</i> , 2:165-176, 1992.
<i>AN</i>	C83	Loke et al., "Delivery of c-myc Antisense Phosphorothioate Oligodeoxynucleotides to Hematopoietic Cells in Culture by Liposome Fusion: Specific Reduction in c-myc Protein Expression Correlates with Inhibition of Cell Growth and DNA Synthesis," <i>Current Topics in Microbiology and Immunology, Mechanisms in B-Cell Neoplasia</i> , 141:282-289, 1988.

Examiner:

Date Considered:

3/2/98

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)Atty. Docket No.
UTXC:504/CODSerial No.
08/726,211

List of Patents and Publications for Applicant's

Applicant

Tormo et al.

Filing Date:
October 4, 1996Group:
~~1805~~ 1636**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
NA	C84	Marin <i>et al.</i> , "Complementation and Cell Death Regulation By Bcl-2, p53 and c-myc During <i>In Vivo</i> Lymphomagenesis," <i>Journal of Cellular Biochemistry</i> , Supplement 19B, p 286, Abstract B8-224, February 5- March 15, 1995.
BA	C85	McDonnell <i>et al.</i> , "Cell Death Suppression by Bcl-2 Is Associated with Altered Nuclear-Cytoplasmic Trafficking," <i>Proceedings of the American Association for Cancer Research</i> , 37:16, Abstract 111, March 1996.
AN	C86	Ropert <i>et al.</i> , "Inhibition of the Friend Retrovirus by Antisense Oligonucleotides Encapsulated in Liposomes: Mechanism Action," <i>Pharmaceutical Research</i> , 10(10):1427-1433, April 1993.
ON	C87	Skorski <i>et al.</i> , "Gene-targeted Specific Inhibition of Chronic Myeloid Leukemia Cell Growth by BCR-ABL Antisense Oligodeoxynucleotides," <i>Folia Histochemica et Cytobiologica</i> , 29(3):85-90, 1991.
AN	C88	Tari <i>et al.</i> , "Liposomal Delivery of Methylposphonate Antisense Oligodeoxynucleotides in Chronic Myelogenous Leukemia," <i>Blood</i> , 84(2):601-607, July 1994.
AN	C89	Thierry <i>et al.</i> , "Intracellular Availability of Unmodified, Phosphorothioated and Liposomally Encapsulated Oligodeoxynucleotides for Antisense Activity," <i>Nucleic Acids Research</i> , 20(21):5691-5698, September 1992.
AN	C90	Thierry <i>et al.</i> , "Liposomal Delivery as a New Approach to Transport Antisense Oligonucleotides," <i>Gene Regulation, Biology of Antisense RNA and DNA</i> , 1:47-161, 1992.
M	C91	Thierry <i>et al.</i> , "Modulation of multidrug Resistance by Antisense Oligodeoxynucleotides Encapsulated by Liposomes," <i>Proceedings of the American Association for Cancer, Preclinical Pharmacology/Experimental Therapeutics</i> , Abstract 2578, 32:443, March 1991.
M	C92	Thierry <i>et al.</i> , "Overcoming Multidrug Resistance in Human Tumor Cells Using Free and Liposomally Encapsulated Antisense Oligodeoxynucleotides," <i>Biochemical and Biophysical Research Communications</i> , 190(3):952-960, February 1994.
N	C93	Tormo <i>et al.</i> , "Antitumor Activity of Liposomal-Bcl-2-Antisense Oligonucleotides in Follicular Lymphoma," <i>Proceedings of the American Association for Cancer Research</i> , 37:173, Abstract 1190, March 1996.
M	C94	U.S. Patent Application 08/520,385 Filed August 29, 1995 Inventors G. Lopez-Berestein and A.M. Tari

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)